Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or Stage IV Prostate Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or Stage IV Prostate Cancer.

Key facts

Study ID

NCT00003516

Run by

Burzynski Research Institute

People needed

16

Starts

1996-03-27

Expected to finish

2004-03-18

Last updated by the study team

2018-02-05

Who can join

Age: 18 and older, up to 99. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.